{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:49:48Z","timestamp":1765486188180},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40273-018-0644-3","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T03:16:48Z","timestamp":1522034208000},"page":"1073-1081","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"36","author":[{"given":"Xavier","family":"Armoiry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Connock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Tsertsvadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewen","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Melendez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pam","family":"Royle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"644_CR1","unstructured":"Ixazomib citrate in combination with lenalidomide and dexamethasone for relapsed refractory multiple myeloma: a single technology appraisal. Warwick Evidence; 2017."},{"issue":"3","key":"644_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2710.2008.00920.x","volume":"33","author":"X Armoiry","year":"2008","unstructured":"Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther. 2008;33(3):219\u201326.","journal-title":"J Clin Pharm Ther"},{"key":"644_CR3","unstructured":"Haematological Malignancy Research Network (HMRN). Myeloma. 2017. \n                    https:\/\/www.hmrn.org\/statistics\/disorders\/24\n                    \n                  . Accessed 21 Feb 2017."},{"issue":"17","key":"644_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"644_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000375392","volume":"38","author":"S Cartier","year":"2015","unstructured":"Cartier S, Zhang B, Rosen VM, Zarotsky V, Bartlett JB, Mukhopadhyay P, et al. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data. Oncol Res Treat. 2015;38(3):88\u201394.","journal-title":"Oncol Res Treat"},{"key":"644_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"24","key":"644_CR7","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"644_CR8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1536867X0900900103","volume":"9","author":"IR White","year":"2009","unstructured":"White IR. Multivariate random-effects meta-analysis. Stata J. 2009;9(1):40\u201356.","journal-title":"Stata J"},{"issue":"21","key":"644_CR9","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133\u201342.","journal-title":"N Engl J Med"},{"issue":"21","key":"644_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123\u201332.","journal-title":"N Engl J Med."},{"issue":"1","key":"644_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3324\/haematol.2014.112037","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, et al. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015;100(1):100\u20136.","journal-title":"Haematologica"},{"key":"644_CR12","doi-asserted-by":"crossref","unstructured":"Montefusco V, Capecchi M, Galli M, Pezzatti S, Patriarca F, Gherlinzoni R, et al. Bortezomib versus lenalidomide in multiple myeloma patients at first relapse: first interim analysis of a phase III study [abstract no. PO-334]. 15th International Myeloma Workshop; 2015.","DOI":"10.1016\/j.clml.2015.07.565"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1038\/bcj.2014.77","volume":"4","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Cancer J. 2014;4:e257. \n                    https:\/\/doi.org\/10.1038\/bcj.2014.77\n                    \n                  .","journal-title":"Blood Cancer J."},{"key":"644_CR14","unstructured":"National Institute for Health and Care Excellence. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib: technology appraisal guidance [TA338]. 2015. \n                    https:\/\/www.nice.org.uk\/guidance\/ta338\n                    \n                  . Accessed 3 Jan 2017."},{"key":"644_CR15","unstructured":"National Institute for Health and Care Excellence. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma, technology appraisal guidance [TA505]. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/ta505\n                    \n                  . Accessed 19 Mar 2018."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0644-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0644-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0644-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T21:11:59Z","timestamp":1553548319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0644-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0644-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2018,3,26]]},"assertion":[{"value":"26 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This report was commissioned by the National Institute for Health Research Health Technology Assessment Programme as project number ID807.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xavier Armoiry, Martin Connock, Alexander Tsertsvadze, Ewen Cummins, GJ Melendez-Torres, Pam Royle, and Aileen Clarke have no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}